Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Abstract: The present disclosure relates to cells for intravascular transplantation having hemocompatibility in which the blood coagulation mechanism and thrombosis reaction are inhibited by artificially modifying the F3 gene encoding CD142 that is an initiator of blood coagulation, using gene scissors technology to reduce or suppress the expression or activity of CD142, a method of producing the same, and a use thereof for preventing or treating liver disease and diabetes.

Abstract: The present disclosure provides a substituted piperidine compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof having activity of degrading androgen receptor (AR). The present disclosure also provides a composition comprising such a substituted piperidine compound or a pharmaceutically acceptable salt thereof. The present disclosure also provides a medical use of a substituted piperidine compound according to the present disclosure, a salt thereof, and a composition comprising the same for the treatment or prophylaxis of AR-related diseases. The present disclosure also provides a method for treating or preventing an AR-related disease comprising administering to a subject in need thereof an effective amount of a substituted piperidine compound according to the present disclosure, a salt thereof, or a composition comprising the same.

Abstract: The present disclosure provides a substituted piperidine compound of Chemical Formula 1, wherein X is CR3, or a pharmaceutically acceptable salt thereof having activity of degrading androgen receptor (AR). The present disclosure also provides a composition comprising such a substituted piperidine compound or a pharmaceutically acceptable salt thereof. The present disclosure also provides a medical use of a substituted piperidine compound according to the present disclosure, a salt thereof, and a composition comprising the same for the treatment or prophylaxis of AR-related diseases. The present disclosure also provides a method for treating or preventing an AR-related disease comprising administering to a subject in need thereof an effective amount of a substituted piperidine compound according to the present disclosure, a salt thereof, or a composition comprising the same.

Abstract: Mesenchymal stem cells, a preparation method therefor, and a cell therapeutic agent using same have hemocompatibility since thrombosis thereof is suppressed after the expression or activation level of blood coagulation initiating factor CD142 is reduced or inhibited. When intravascularly administered, the mesenchymal stem cells have improved hemocompatibility since thrombosis thereof, which can be caused by the administered mesenchymal stem cells, is suppressed.

Abstract: Provided are mesenchymal stem cells, a preparation method therefor, and a use thereof, the mesenchymal stem cell having oxidative stress resistance by reducing or inhibiting the expression or activity level of KEAP1, which is a negative regulator of Nrf2, so as to increase the activity of Nrf2.

Abstract: The present invention relates to a method for predicting the reactivity of a cancer-targeted therapeutic agent, in which various types of target proteins targeted by a cancer-targeted therapeutic agent are simultaneously quantified through triple quadrupole mass spectrometry. The inventors of the present invention carefully selected peptide sequences with high selectivity in nanoflow liquid chromatography-triple quadrupole mass spectrometry, in response to clinical needs, and optimized peptide combinations and experimental conditions to enable multiple peptide quantification.

Abstract: The present disclosure provides a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof having activity of degrading androgen receptor (AR). The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure also provides a medical use of a compound according to the present disclosure, a salt thereof, and a composition comprising the same for the treatment or prophylaxis of AR-related diseases. The present disclosure also provides a method for treating or preventing an AR-related disease comprising administering to a subject in need thereof an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising the same.

Abstract: Provided are a biomarker for diagnosing of the level of senescence, a composition and kit for diagnosing of the level of senescence to detect the biomarker, and a method of diagnosing the same. According to the composition and kit for the diagnosis of the level of senescence and the method of diagnosing senescence, the level of senescence of a subject is easily diagnosed, the health conditions of the subject are monitored, and a senescence-associated disease is prevented or diagnosed.

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Abstract: Disclosed is an electronic device. The present electronic device comprises a display, and a processor configured to display, through the display, a UI based on use patterns of a plurality of devices connected to a same network, wherein the UI comprises a device axis and a time axis, and provides information related to use of at least one device in a region where the device axis and the time axis intersect each other.

Abstract: Provided are a biomarker for diagnosing of the level of senescence, a composition and kit for diagnosing of the level of senescence to detect the biomarker, and a method of diagnosing the same. According to the composition and kit for the diagnosis of the level of senescence and the method of diagnosing senescence, the level of senescence of a subject is easily diagnosed, the health conditions of the subject are monitored, and a senescence-associated disease is prevented or diagnosed.

Abstract: Disclosed is an electronic device. The present electronic device comprises a display, and a processor configured to display, through the display, a UI based on use patterns of a plurality of devices connected to a same network, wherein the UI comprises a device axis and a time axis, and provides information related to use of at least one device in a region where the device axis and the time axis intersect each other.

Abstract: Disclosed are a method for detecting a biomolecule including: immobilizing a nucleic acid aptamer capable of specifically binding to a biomolecule to be detected on the surface of a bead on which fluorophores are arranged; hybridizing the nucleic acid aptamer with a guard nucleic acid (g-nucleic acid) labeled with a quencher to quench fluorescence; and reacting a sample including the biomolecule to be detected with the nucleic acid aptamer and detecting a fluorescence signal emitted as the biomolecule binds with the nucleic acid aptamer and the g-nucleic acid labeled with the quencher is separated, and a device for detecting a biomolecule for conducting the detection method. The present disclosure allows for effective, convenient and fast detection of the biomolecule to be detected, enables quantitative analysis, and enables detection of even a trace amount of sample.

Abstract: Provided are an anthracene-based compound represented by Formula 1 or 2 and an organic light emitting device employing the same: where R is a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, a substituted or unsubstituted C1-C20 alkyl group, a substituted or unsubstituted C3-C20 cycloalkyl group, a substituted or unsubstituted C5-C30 heterocycloalkyl group, a substituted or unsubstituted C1-C20 alkoxy group, a substituted or unsubstituted C6-C30 aryl group, a substituted or unsubstituted C6-C30 aralkyl group or a substituted or unsubstituted C2-C30 heteroaryl group, L is a bivalent linking group and a substituted or unsubstituted C6-C30 arylene group or a substituted or unsubstituted C2-C30 heteroarylene group, and m is an integer of 0 to 3.

Abstract: Provided are an anthracene-based compound represented by Formula 1 or 2 and an organic light emitting device employing the same: where R is a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, a substituted or unsubstituted C1-C20 alkyl group, a substituted or unsubstituted C3-C20 cycloalkyl group, a substituted or unsubstituted C5-C30 heterocycloalkyl group, a substituted or unsubstituted C1-C20 alkoxy group, a substituted or unsubstituted C6-C30 aryl group, a substituted or unsubstituted C6-C30 aralkyl group or a substituted or unsubstituted C2-C30 heteroaryl group, L is a bivalent linking group and a substituted or unsubstituted C6-C30 arylene group or a substituted or unsubstituted C2-C30 heteroarylene group, and m is an integer of 0 to 3.

Abstract: Disclosed are a method for detecting a biomolecule including: immobilizing a nucleic acid aptamer capable of specifically binding to a biomolecule to be detected on the surface of a bead on which fluorophores are arranged; hybridizing the nucleic acid aptamer with a guard nucleic acid (g-nucleic acid) labeled with a quencher to quench fluorescence; and reacting a sample including the biomolecule to be detected with the nucleic acid aptamer and detecting a fluorescence signal emitted as the biomolecule binds with the nucleic acid aptamer and the g-nucleic acid labeled with the quencher is separated, and a device for detecting a biomolecule for conducting the detection method. The present disclosure allows for effective, convenient and fast detection of the biomolecule to be detected, enables quantitative analysis, and enables detection of even a trace amount of sample.

Abstract: The present invention provides an aromatic heterocyclic compound represented by Formula 1 below, an organic light-emitting diode including an organic layer comprising the aromatic heterocyclic compound, and a method of manufacturing the organic light-emitting diode: wherein A, Ar1, Ar2, n, m, and k are as described in the detailed description of the present invention.

Abstract: Provided are an aromatic heterocyclic compound represented by Formula 1 below, an organic light emitting diode including the same, and a method of manufacturing the organic light emitting diode: wherein descriptions of Formula 1 are the same as defined in the detailed description of the invention.

Abstract: In a method of forming a pattern of an organic light emitting device (OLED), an organic material is evaporated in a predetermined pattern by using a pre-patterned heating element, and the evaporated organic material is transferred to a substrate where the OLED is formed. The method includes preparing a template having a heating element in a pattern corresponding to a multilayered structure of an OLED including a plurality of functional layers; forming an organic layer on the heating element; drawing a substrate for the OLED near to the heating element of the template; and transferring the organic layer on the heating element to the substrate by evaporating the organic layer using the heating element.